Assessment of the probiotic Symprove as a dietary supplement in patients with symptomatic diverticular disease: a double blind randomised placebo controlled trial

King's College Hospital (UK)0 个研究点目标入组 200 人开始时间: 2013年2月8日最近更新: 2018年1月15日

适应症

试验速览

暂无简介。

•1. Have a documented episode of diverticulitis as assesses clinically, on CT scans and a raised serological markers of inflammation
•2. Have problematic symptoms associated with established diverticular disease
•3. Aged between 18 and 80 years
•4. Are on no treatment or have been on stabile medication for at least 6 weeks for diverticular disease
•5. Willing and able to provide a written informed consent

•1. Aged less than 18 years and greater than 80 years
•2. Severe disease (ongoing severe active diverticulitis) as defined by hemoglobin < 8.0 g/dl, white blood cell count >20,000 cells/mm3, temperature >38.5°C, albumin < 25 g/dl
•3. Diverticular complications such as recto-vaginal or bladder fistula, abscess, etc.
•4. Severe respiratory, cardiovascular, neurological, psychiatric, rheumatological diseases
•5. Undergone major intestinal resections
•6. Patients with malignancy
•7. On NSAIDs
•8. Pregnancy or actively seeking pregnancy
•9. History of intolerance or allergy to probiotics
•10. Current drug or alcohol dependence syndrome
•11. Pregnancy
•12. Patients with severe learning difficulties

发起方

King's College Hospital (UK)